

Supplementary Table S1. Baseline levels, statin levels, and statin-induced changes of plasma biomarkers measured in 901 CAP participants with measurements of PCSK9 levels available. Values are mean \pm standard deviation.

| Phenotype | Baseline | Statin | Delta | % Change | Delta Log |
|----------------------------------|-----------------|-----------------|-------------------|-------------------|--------------------|
| PCSK9 (nM) | 2.66 \pm 0.92 | 3.48 \pm 1.22 | 0.817 \pm 1.059 | 37.9 \pm 51.9% | 0.266 \pm 0.326 |
| LDL-cholesterol (mg/dl) | 131. \pm 33.5 | 77.8 \pm 24.5 | -53.0 \pm 25.5 | -39.7 \pm 15.6% | -0.537 \pm 0.253 |
| APOB (mg/dl) | 94.2 \pm 21.5 | 66.0 \pm 17.3 | -28.3 \pm 15.5 | -29.3 \pm 13.5% | -0.364 \pm 0.185 |
| Total cholesterol (mg/dl) | 209. \pm 36.3 | 154. \pm 28.5 | -55.1 \pm 27.9 | -25.7 \pm 11.2% | -0.308 \pm 0.146 |
| HDL-cholesterol (mg/dl) | 53.8 \pm 16.6 | 56.1 \pm 17.5 | 2.29 \pm 7.48 | 5.15 \pm 13.8% | 0.0415 \pm 0.133 |
| Triglycerides (mg/dl) | 121. \pm 69.5 | 100. \pm 64.3 | -21.2 \pm 56.7 | -11.4 \pm 40.0% | -0.201 \pm 0.391 |